中国药物经济学2025，Vol.20Issue(6)：56-62,67,8.DOI:10.12010/j.issn.1673-5846.2025.06.009
骨松宝制剂治疗原发性骨质疏松症疗效与安全性的Meta分析
Efficacy and Safety of Gusongbao Formulation in the Treatment of Primary Osteoporosis:A Meta-analysis
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of Gusongbao preparations in the treatment of primary osteoporosis(POP).Methods The relevant literatures on the treatment of POP with Gusongbao preparations published publicly in computer retrieval databases such as China National Knowledge Infrastructure(CNKI),Wanfang Data Knowledge Service Platform,Chinese Journal Full-text Database,CBM,PubMed,Cochrane Library,and Embase were retrieved.The retrieval time was from the establishment of the databases to October 2024.According to the pre-determined inclusion and exclusion criteria,literature screening and data extraction were independently conducted by two researchers.The quality of the included literature was evaluated using the risk of bias assessment tool,and the extracted data was statistically analyzed using RevMan 5.4 software.Results Ultimately,13 articles were included,involving 2 261 patients,among which 783 were in the experimental group and 1 478 were in the control group.The results of the meta-analysis showed that the Gusongbao preparation improved the bone mineral density of lumbar vertebrae L2～4(MD=0.04,95%CI:0.02～0.06,Z=4.03,P＜0.000 1)and femoral neck bone mineral density(MD=0.03,95%CI:0.00～0.05,Z=2.24,P=0.03)and in reducing the low back pain score(MD=-2.23,95%CI:-3.36～-1.09,Z=3.85,P=0.000 1),it was superior to the control group treatment,and the clinical efficacy was also significantly improved(RR=1.14,95%CI:1.03～1.27,Z=2.41,P=0.02).The adverse reactions were mainly mild gastrointestinal discomfort,rash,etc.However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(RR=0.88,95%CI:0.54～1.44,Z=0.51,P=0.61).Conclusion Gusongbao-related formulations demonstrate clinically significant efficacy in treating POP with only mild adverse effects.However,further large-scale clinical trials are warranted to confirm their long-term efficacy and safety,thereby providing more robust evidence for the treatment of patients with primary osteoporosis.关键词
原发性骨质疏松症/Meta分析/骨宝松制剂Key words
Primary osteoporosis/Meta-analysis/Gusongbao formulations分类
医药卫生引用本文复制引用
王栋,晏茜昱,范鸣翔,伍英杰,陈茂彦,谭石祥,许和贵..骨松宝制剂治疗原发性骨质疏松症疗效与安全性的Meta分析[J].中国药物经济学,2025,20(6):56-62,67,8.基金项目
贵州省科技计划项目(黔科合基础-ZK[2022]一般523) （黔科合基础-ZK[2022]一般523）
贵州省卫生健康委科学技术基金项目(gzwkj2024-402) （gzwkj2024-402）
